Spectrum Brands Holdings, Inc. (SPB): what the price assumes

In the published model solve dated 2026-Q2, anchored at $90.55, Spectrum Brands Holdings, Inc. (SPB) is priced for today's economics sustained for ~12.0 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-11.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/SPB

Headline

FieldValue
TickerSPB
CompanySpectrum Brands Holdings, Inc.
Sector / IndustryIndustrials
Current price$90.55/sh
CompositionProduct Sales 99% / Licensing 1% / Service and other 0%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)8.5%
Operating margin today4.7%
Margin expansion (value-band)+3.8pp
Must persist for12.0y
Multiple paid20x operating income

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 14.3% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.3 years.

Reconcile: at the x-ray's 9.3% required return this reads ~16.3%/yr; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history+0.46σ
cohort percentile (of 221 peers)44
sustained it ~10 years at this level15%
implied end-window share0%

Valuation X-Ray

The price is supported by earnings-power and relative-multiple and growth-DCF value, while asset-based lands below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.85x5expensive
Earnings0.91x5justifies
Relative0.97x2justifies
Growth0.78x3justifies

Families that justify the price: Earnings, Relative, Growth Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.0%); the inversion above states its own rate.

Per-Model Detail (n=15)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$141.190.64xyesFCF base $0.3B, growth -3% (input: historical growth), terminal g 0.5%, WACC 7.0%, 5yr projection
DCF Exit MultipleGrowth$116.650.78xyesExit EV/EBITDA: 8.8x / 10.8x / 12.8x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelativenoP/E 18x (static sector reference · 2026-04), scenarios: 15.2x / 18.0x / 20.8x (bear / base = reference held flat / bull), EV/EBITDA 12x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$58.461.55xyesBV/sh $81.58, ROE (TTM) 6.6%, ke 9.3%
Two-Stage Excess ReturnAsset$48.841.85xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$51.321.76xyesRev $2.8B, growth -3% (input: historical growth; tapered), Terminal P/S: 0.6x / 0.7x / 0.9x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$61.681.47xyesEPS $5.14, growth 2% (input: historical EPS growth), PEG=8.37 (Overvalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$17.955.04xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.12B × (1−39%) / WACC 7.0% → EPV (no growth)
Residual IncomeAsset$47.511.91xyesBV $81.58 + 5yr PV of (ROE (TTM) 6.6% − Kₑ 9.3%) × BV; BV grows 4.3%/yr
Graham NumberAsset$97.130.93xyes√(22.5 × EPS $5.14 × BVPS $81.58) — Graham's conservative floor
EV/EBITDA RelativeRelativenoEBITDA $0.25B × sector EV/EBITDA 12.0x
FCF YieldEarnings$108.740.83xyesFCF $289.9M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$99.040.91xyesSBC-adj FCF $0.27B (FCF $0.29B − SBC $0.02B) capitalized at Kₑ
Ben Graham FormulaEarnings$165.850.55xyesEPS $5.14 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$12.327.35xyesBV $81.58 × (ROIC 1.1% / WACC 7.0%)
P/Sales SectorRelativenoRevenue $2.82B × sector P/S 2.5x
PEG Fair ValueRelative$192.750.47xyesEPS $5.14 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$55.571.63xyesEPS $5.14 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Global Pet Careoperatingenterprise$1.1bwithheldunresolved no unit value
Home & Gardenoperatingenterprise$572.8mwithheldunresolved no unit value
Home & Personal Careoperatingenterprise$1.2bwithheldunresolved no unit value

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

FieldValue
Net debt$559.9m
Net debt / NOPAT (after-tax)6.97x
Net debt / operating income (pre-tax)4.26x
Interest coverage4.3x
Share count CAGR (buyback)-13.1%
Burning cashno

Bullet Takeaways

Bull Case

The most surprising number in the Spectrum Brands data is not on the income statement. The share count has fallen about 13% per year for four consecutive years. Compounded, that means the company has retired roughly two-fifths of itself, and it kept going through fiscal 2026: 0.6 million shares repurchased for $36 million in the December quarter, followed by a fresh $300 million authorization on top of a $0.47 quarterly dividend. For a $1.9 billion market cap, a $300 million authorization is material in a way megacap buybacks never are; each completed tranche mechanically concentrates the remaining owners in the pet, garden, and appliance brands underneath.

What the owners are being concentrated into is improving where it counts. Global Pet Care, the crown jewel, returned to growth in fiscal 2026, and the second quarter showed the mix working: net sales rose 4.9%, net income from continuing operations was $22.5 million against $1.8 million a year earlier, adjusted EBITDA margin expanded 40 basis points despite tariffs, and management raised its full-year adjusted EBITDA outlook to low-to-mid single digit growth. Pet food and aquatics are replenishment categories with resilient demand, and the segment has structural insulation the filing spells out: GPC has "major suppliers outside of China, which has allowed it to move production more swiftly to alternative supply" [FY2025 10-K, accession 0000109177-25-000043].

The last piece is addition by subtraction. Home and Personal Care, the segment that has dragged organic sales down double digits, is being carved out: Oaktree invested $127 million in May 2026, split between preferred equity and a first-lien term loan, nonrecourse to the parent, valuing HPC at about six times trailing EBITDA and explicitly advancing the planned separation. A Spectrum Brands without HPC is a higher-margin, less tariff-exposed pet and garden company, and the market currently prices the whole at a discount to what the earnings-based and peer-multiple lenses would defend. Shrinking the share count while the worst segment exits is a two-sided squeeze on the per-share value.

Bear Case

Name the structural truth first: this stock is cheap because parts of the business are deteriorating, and cheap-because-deteriorating is a category, not a bargain. Home and Personal Care sales fell 5.5% in the March quarter with organic sales down 10.7% on category softness in North America and Europe, running six-month organic declines near 11%, and the December quarter opened the year with adjusted EBITDA down 19.5%. The Oaktree transaction that bulls read as a catalyst also functions as a price disclosure: a sophisticated buyer sized HPC at about six times trailing EBITDA, a multiple that says structurally challenged, and took first-lien and preferred positions rather than common equity.

The cost base is hostage to trade policy. The 10-K is unusually direct: products sold in the U.S. are "manufactured in or sourced from China" in large part, tariffs have "required us to increase prices to our customers" or "resulted in lowering our gross margin on products sold", and after the April 2025 tariff escalation the company "temporarily paused virtually all finished goods imports out of China" [FY2025 10-K, accession 0000109177-25-000043]. A consumer company that pauses its own supply chain to dodge tariff rates is managing policy volatility in real time, with the retail shelf as the penalty for guessing wrong. Distribution is concentrated too: in pet care, Amazon and Walmart represented approximately 34% of segment sales in fiscal 2025 [FY2025 10-K, accession 0000109177-25-000043], and the Tristar litigation reminds that HPC acquisitions have already produced "damages and losses incurred by the HPC segment" with "no guarantees and assurances that recoveries" arrive [FY2025 10-K, accession 0000109177-25-000043].

Under all of it sits leverage that makes the buyback double-edged. Net debt of $560 million runs about 4.3 times trailing operating income with interest coverage of 4.3 times, thin for a business whose EBITDA fell double digits two quarters ago. Retiring 13% of the share count annually is management conviction, but it is also cash leaving a leveraged balance sheet during a tariff war. And the price is less forgiving than the headline multiples suggest: worked through at the demanding cost of capital this profile commands, today's price embeds operating growth persisting near its feasible ceiling for a couple of decades, a persistence only about 15% of comparable fast-growers have sustained even ten years. If pet care growth stalls or the HPC separation stumbles, the deteriorating pieces set the multiple, not the improving ones.

Valuation

Two honest readings of this price disagree, and the disagreement is the analysis. On the static lenses the stock looks modestly cheap: the price sits about 20 to 26% below where earnings-power, peer-multiple, and cash-flow arithmetic land. On the discounted-growth solve it looks demanding: at roughly 20 times trailing operating income and the high cost of capital this equity's volatility commands (about 18%), the price implies operating growth held near its self-funding ceiling for something like 24 years, a figure to hold loosely since each point of discount rate moves that horizon by years. The bridge between the readings is risk: the multiple lenses price the earnings as they are; the growth solve charges heavily for how uncertain those earnings have proven, with trailing operating income around $131 million on the EDGAR quarterly basis (a separate record basis reads about a quarter higher; the two are different measurement bases, both labeled here).

The asset lens dissents in the other direction, with the price about 70% above book-value-based arithmetic, which is the ordinary signature of a brands business: the value lives in Global Pet Care trademarks and shelf positions, not in plant. Sector sales multiples read the stock at about a quarter of the sector's norm, which mostly measures how differently the market treats appliance-adjacent revenue versus staples revenue. The pattern overall is a value read resting on earnings durability, with the HPC separation as the event that would re-sort which peer set the remaining company gets compared against; the Oaktree mark of about six times trailing EBITDA for HPC gives the market a hard external reference for the piece being removed.

The balance sheet is the constraint on the whole construction. Net debt of $560 million is about 4.3 times trailing operating income (roughly 7 times after-tax), interest coverage is 4.3 times, the company is not burning cash, and the share count is down 13.1% a year over four years. Fiscal 2026 guidance calls for flat to low-single-digit sales growth with about 50% of adjusted EBITDA converting to adjusted free cash flow; that conversion funds the dividend and buyback only while EBITDA holds. The price needs the pet-and-garden core to keep growing through the tariff regime the 10-K describes, in which tariffs have already "resulted in lowering our gross margin on products sold" [FY2025 10-K, accession 0000109177-25-000043].

Catalysts

The separation of Home and Personal Care is the live event. In May 2026 Oaktree agreed to invest $127 million in the HPC business, split between preferred equity and a first-lien term loan, nonrecourse to Spectrum Brands, valuing the segment at about six times trailing EBITDA and explicitly funding the standalone path. Completion mechanics, timing, and what the remaining pet-and-garden company retains are the items each subsequent print should clarify.

The operating trajectory improved through the first half. After a soft December quarter (net sales $677 million, down 3.3%; adjusted EBITDA $62.6 million, down 19.5%), the March quarter delivered 4.9% sales growth, 1.5% organic, net income from continuing operations of $22.5 million versus $1.8 million a year earlier, and a raised full-year adjusted EBITDA outlook of low-to-mid single digit growth on pet care and home-and-garden strength. The fiscal Q3 print (summer 2026) tests whether the raise survives peak home-and-garden season and the current tariff schedule.

Capital returns continue on their aggressive cadence: a $300 million repurchase authorization approved in February against a $1.9 billion market cap, plus the $0.47 quarterly dividend. The pace of buyback execution each quarter, read against the leverage the balance sheet already carries, is the cleanest tell on how management weighs equity concentration against debt reduction.

Peer Cohorts (Per Segment, With Filing Citations)

Global Pet Care (reported)

Home & Garden (reported)

Home & Personal Care (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q1 FY2026 earnings release, February 5, 2026 · Q2 FY2026 earnings release and call, May 2026 · Q2 FY2026 earnings release, May 2026 · Q2 FY2026 earnings call, May 2026

View the full interactive SPB report on boothcheck